Lumasiran
Oligonucleotide
Overview
Lumasiran is a oligonucleotide active pharmaceutical ingredient (ChEMBL CHEMBL4297779).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Lumasiran expires 20 Nov 2038 and exclusivity 6 Oct 2029. Generic API sourcing typically opens up once these lapse.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.